Online,

Boston,

MA,

US,

ZIP: 02108

Phone: +4402031418700

The 2nd Ligase Targeting Drug Development Summit returns virtually with new insight and data from pioneers in the field to delve deep into ligase biology, assays to investigate functions as well as screening tools for optimum ligand identification and validation.

This forum will provide an unrivalled meeting-point for industry leaders, in order to strategically accelerate and de-risk the process of identifying, validating and therapeutically leveraging cell and tissue specific Ubiquitin E3 ligases for degradation or modulation of targets of interest.

Tickets    https://go.evvnt.com/965940-2?pid=1052
Brochure https://go.evvnt.com/965940-3?pid=1052

Prices:
Conference + Workshop Day or Focus Day (Drug Developer Pricing) USD 2946.00,
Conference Only (Drug Developer Pricing) USD 1899.00,
Conference + Workshop Day or Focus Day (Standard Rate) USD 3696.00,
Conference Only (Standard Rate) USD 2349.00,
Conference + Workshop Day or Focus Day (Academic Pricing) USD 2396.00,
Conference Only (Academic Pricing) USD 1649.00

Category: Conferences | Science, Health & Medicine

Ellen Vieux, Senior Research Scientist, C4 Therapeutics, Jennifer Johnston, Chief Executive Officer, NysnoBio, Katie Digianantonio, Senior Research Scientist, Arvinas, Sandra Kumper, Investigator, GSK, Dan Robbins, Associate Director, Medicinal Chemistry, Nurix Therapeutics, Jennifer Venable, Senior Scientific Director, The Janssen Pharmaceutical Companies of Johnson & Johnson, Radosław Nowak, Senior Scientist, Cancer Biology, Dana-Farber Cancer Institute, Sharon Shechter, Director of Platform Integration, Roivant Sciences, Hakryul Jo, Associate Director, Platform Biology, Kymera Therapeutics, Jeff McKenna, Associate Director, Novartis institutes for Biomedical Research, Ryan Potts, Head of Induced Proximity Platform, Amgen, Satpal Virdee, MRC Investigator & Professor of Chemical Biology, MRC Protein Phosphorylation & Ubiquitylation Unit, University of Dundee, Benjamin Ruprecht, Director of Translational Proteomics, Roivant Sciences, Kevin Moreau, Associate Director, Safety Innovation & PROTAC Science Lead, AstraZeneca, Matthieu Schapira, Principal Investigator, Structural Genomics Consortium, University of Toronto, Smaranda Bodea, Associate Principal Scientist, Chemical Biology, Merck Research Laboratories, Gary Kleiger, Associate Professor, University of Nevada, Las Vegas, George Burslem, Assistant Professor, University of Pennsylvania, Richard Huang, Senior Principal Scientist & Group Leader, Bristol-Myers Squibb, Wei Zhang, Assistant Professor, University of Guelph, Corey Strickland, Vice President Molecular Technology, Proteovant, Luca Busino, Assistant Professor in Cancer Biology, University of Pennsylvania, Sarath Ramachandran, Postdoctoral Scientist, University of Dundee, Wu Du, Senior Vice President, Hinova Pharmaceuticals, Michael Rape, Investigator, HHMI; Professor; Dr. K. Peter Hirth Chair of Cancer Biology, HHMI/UC Berkeley, Qianhe Zhou, Principal Scientist, Foghorn Therapeutics